Roth Capital Transfers Coverage on Cellectar Biosciences (CLRB) at Buy

Roth Capital analyst Jonathan Aschoff assumes primary coverage on Cellectar Biosciences (NASDAQ: CLRB) with a Buy rating and a price target of $10.00.

The analyst comments "CLRB is developing CLR 131, a targeted radiotherapeutic initially being tested in relapsed and refractory hematological malignancies such as DLBCL and multiple myeloma (MM). CLR 131's tumor selectivity comes from its ability to selectively bind to regions of a tumor cell membrane that are densely comprised of tumor-specific lipids, and then become internalized. CLRB's most impactful 2020 catalysts include additional readouts from its Phase 1 MM trial and the conclusion of its Phase 2 CLOVER-1 trial in B cell malignancies."

For an analyst ratings summary and ratings history on Cellectar Biosciences click here. For more ratings news on Cellectar Biosciences click here.

Shares of Cellectar Biosciences closed at $2.60 yesterday.

You May Also Be Interested In